Esperion Therapeutics
ESPR
ESPR
165 hedge funds and large institutions have $930M invested in Esperion Therapeutics in 2020 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 58 increasing their positions, 48 reducing their positions, and 36 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less first-time investments, than exits
New positions opened: | Existing positions closed:
31% less call options, than puts
Call options by funds: $9.76M | Put options by funds: $14.2M
43% less capital invested
Capital invested by funds: $1.62B → $930M (-$691M)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Holders
165
Holding in Top 10
3
Calls
$9.76M
Puts
$14.2M
Top Buyers
| 1 | +$41.7M | |
| 2 | +$24.4M | |
| 3 | +$16.2M | |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$7.62M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.96M |
Top Sellers
| 1 | -$10.2M | |
| 2 | -$8.73M | |
| 3 | -$5.45M | |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$5.42M |
| 5 |
Goldman Sachs
New York
|
-$5.33M |